191 results
Page 3 of 10
8-K
EX-99.1
1sdwpzye1n rgq
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
EX-99.1
zeclesryr64cowby
29 Apr 21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
10:07am
8-K
EX-99.1
48va cyey
23 Mar 21
Other Events
8:21am
8-K
EX-99.1
3gq0rg6g605p3lq569c3
11 Mar 21
Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
8:38am
8-K
EX-1.1
j1dy ib571qa
17 Feb 21
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8:06am
424B5
yezadmx95if4tbx
16 Feb 21
Prospectus supplement for primary offering
5:11pm
424B5
8brzbg
16 Feb 21
Prospectus supplement for primary offering
6:03am
8-K
EX-99.2
1iyiv nzc8etkii1j
10 Feb 21
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
9:03am
S-8
zj7zirtvrxemhf m8
19 Jan 21
Registration of securities for employees
12:00am
8-K
EX-99.2
b8oz5hxh
29 Dec 20
Other Events
4:24pm
8-K
EX-99.1
12z8 rm0h
29 Dec 20
Other Events
4:24pm
8-K
EX-99.1
51r4z75 xgu
22 Dec 20
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
8:34am
8-K
EX-99.1
brvqqcaeo2yckcgx4im
10 Dec 20
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
11:32am
8-K
EX-99.1
2sb6cbn21ns
2 Dec 20
Other Events
8:12am